Okyanos CEO Matt Feshbach Announces Appointment of Institute’s Marketing Executive Erika Rosenthal to International Stem Cell Society (STEMSO) Advisory Board

Adult Stem Cell Therapy Trade Organization Expands Advisory Board After Successful Global Conference with Researchers, Scientists, Regulatory Experts, Physicians And Investors

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Erika Rosenthal, Okyanos Heart Institute, adult stem cell therapy

STEMSO Advisory Board and Bahamas Officials

"It is indeed an honor to work with STEMSO to advance their cause to help advance adult stem cell research and therapy worldwide," Erika Rosenthal.

Freeport, The Bahamas (PRWEB) March 10, 2014

Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy has announced the appointment of Okyanos’ senior vice president of marketing, Erika Rosenthal, to the International Stem Cell Society (STEMSO) Advisory Board. She will advise the trade organization in a communications capacity to benefit the membership and the mission.

STEMSO is a member-based, international, non-profit 501(c) 6 trade association which promotes the interests of organizational members of the global, adult stem cell healthcare community. STEMSO provides information, education, resources, advocacy and public awareness for the advancement of adult stem cell research and therapy. The organization recently hosted a global regenerative medicine conference in Freeport, The Bahamas, entitled, “Bridging the Gap: Research to Point of Care” which brought together experts in adult stem cell therapy and regulations to discuss commercialization of therapies for chronic disease in a safe, ethical, and compliant manner.

“STEMSO is an important organization to the field of stem cell therapy and research,” said Feshbach. “Communications and healthcare are both fields in which Erika excels, and so I am pleased to see her lend her expertise for an important cause. I look forward to the Okyanos Heart Institute executive team continuing with such efforts for the greater good of medicine.”

Rosenthal was a 2008 recipient of the National Association of Women Business Owners Business Woman of the Year award, and was recognized in Business Leader Magazine as a “Woman Extraordinaire,” for her business accomplishments and contributions to the non-profit community. She is a former faculty member of the University of California where she taught Marketing and Hospitality Management.

“It is indeed an honor to work with STEMSO to advance their cause to help advance adult stem cell research and therapy worldwide, and to bring together leading researchers, physicians, regulators and scientists to set standards for ethical and responsible delivery of therapies as they become available to the public worldwide,” said Rosenthal. “It is an exciting time in medicine, and STEMSO is greatly needed to bring collaboration and guidance between this impressive member group of thought leaders.”

“STEMSO is pleased to have Erika Rosenthal participate on STEMSO’s Advisory Board,” said Douglas Hammond, president of STEMSO. “Non-profit trade associations are only as strong as their member participation and leadership allows. If other members or prospective organizational members were to support STEMSO as Okyanos Heart Institute and Erika Rosenthal, there would be no limit to STEMSO’s impact in the Regenerative Medicine Industry.”

About Okyanos Heart Institute: (Oh – key – AH – nos)
Based in Freeport, The Bahamas, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name “Okyanos,” the Greek god of rivers, symbolizes restoration of blood flow.

END


Contact

Follow us on: Contact's Google Plus

Attachments